Eli Lilly and Company $LLY Shares Acquired by Steel Grove Capital Advisors LLC

Key Points

• Steel Grove Capital Advisors increased its Eli Lilly stake by 150.6% in the third quarter, bringing its holdings to 1,526 shares valued at approximately $1.765 million. Institutional investors collectively own 82.53% of Lilly’s stock.
• Analysts remain broadly bullish, with a consensus “Moderate Buy” rating and an average price target of $1,313.43. Recent targets reached as high as $1,376, supported by strong Zepbound demand, earnings growth and Lilly’s obesity-drug pipeline.
• Lilly shares fell 1.2% to $1,168.70, despite reporting quarterly revenue growth of 47.7% and adjusted earnings of $8.38 per share, well above estimates. The stock’s premium valuation and higher discontinuation rates for some combination obesity treatments remain key risks.

Steel Grove Capital Advisors LLC boosted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 150.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,526 shares of the company's stock after acquiring an additional 917 shares during the period. Steel Grove Capital Advisors LLC's holdings in Eli Lilly and Company were worth $1,765,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Sax Wealth Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 450.0% during the third quarter. Sax Wealth Advisors LLC now owns 8,410 shares of the company's stock worth $9,731,000 after acquiring an additional 6,881 shares during the period. Terra Nova Asset Management LLC increased its stake in shares of Eli Lilly and Company by 3.0% during the third quarter. Terra Nova Asset Management LLC now owns 2,655 shares of the company's stock worth $3,073,000 after purchasing an additional 78 shares during the period. Fermata Advisors LLC lifted its holdings in Eli Lilly and Company by 12.6% during the 3rd quarter. Fermata Advisors LLC now owns 590 shares of the company's stock worth $683,000 after purchasing an additional 66 shares during the last quarter. NorthCrest Asset Manangement LLC lifted its holdings in shares of Eli Lilly and Company by 4.3% during the third quarter. NorthCrest Asset Manangement LLC now owns 18,180 shares of the company's stock worth $21,263,000 after buying an additional 751 shares in the last quarter. Finally, Haven Capital Group Inc. raised its stake in Eli Lilly and Company by 919.4% in the 3rd quarter. Haven Capital Group Inc. now owns 2,528 shares of the company's stock worth $2,925,000 after purchasing an additional 2,280 shares in the last quarter. Institutional investors own 82.53% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Weiss Ratings raised shares of Eli Lilly and Company from a "buy (b-)" rating to a "buy (b)" rating in a report on Wednesday, August 26th. Leerink Partners raised their price objective on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an "outperform" rating in a report on Thursday, June 25th. HSBC increased their price objective on Eli Lilly and Company from $850.00 to $940.00 and gave the company a "reduce" rating in a report on Thursday, September 10th. TD Cowen reaffirmed a "buy" rating and set a $1,250.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, September 22nd. Finally, Truist Financial upped their price target on Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the company a "buy" rating in a research report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $1,313.43.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts remain optimistic about Lilly’s earnings and growth prospects. Erste Group raised its FY2026 EPS estimate to $36.55 from $36.45 and its FY2027 forecast to $47.30, while RBC reiterated an “outperform” rating with a $1,500 price target. RBC reiterates outperform rating
• Positive Sentiment: Strong demand for Zepbound and other cardiometabolic medicines is supporting expectations that Lilly could raise its full-year revenue outlook. Analysts and investors also see substantial long-term potential in retatrutide, which could become a larger growth driver than Zepbound if clinical results and commercialization proceed successfully. Lilly revenue outlook
• Positive Sentiment: Phase 3b data for a Taltz-Zepbound combination showed improved skin clearance and weight loss in patients with plaque psoriasis and obesity, potentially expanding Lilly’s ability to target overlapping inflammatory and metabolic conditions. Taltz and Zepbound Phase 3b data
• Positive Sentiment: Lilly is collaborating with Prelude Therapeutics to evaluate a cancer drug combination involving PRT13722, Verzenio and Inluriyo, adding another potential pipeline opportunity. Prelude collaboration with Lilly
• Neutral Sentiment: Lilly’s revenue growth substantially exceeds that of major pharmaceutical peers, but its premium earnings multiple leaves less room for execution mistakes. Investor confidence therefore depends heavily on the company’s pipeline and future obesity-drug launches. Lilly valuation and growth outlook
• Negative Sentiment: A combination treatment produced more weight loss than Zepbound alone but also had materially higher discontinuation rates, raising questions about tolerability, adherence and the commercial potential of future obesity therapies. Lilly weight-loss combination study
• Negative Sentiment: Retatrutide is already facing illicit online sales before approval, highlighting potential regulatory, safety and brand risks for Lilly’s highly anticipated obesity pipeline. Retatrutide black-market sales

Eli Lilly and Company Trading Down 1.2%

Shares of Eli Lilly and Company stock traded down $13.92 on Tuesday, hitting $1,168.70. 658,782 shares of the company's stock traded hands, compared to its average volume of 2,945,984. Eli Lilly and Company has a one year low of $783.85 and a one year high of $1,292.65. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The company has a fifty day moving average of $1,175.57 and a two-hundred day moving average of $1,100.31. The company has a market capitalization of $1.10 trillion, a price-to-earnings ratio of 39.25, a price-to-earnings-growth ratio of 1.47 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping analysts' consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The business had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. During the same period in the previous year, the company posted $6.31 earnings per share. The firm's revenue for the quarter was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, sell-side analysts expect that Eli Lilly and Company will post 36.19 earnings per share for the current year.

Insider Transactions at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 2,000 shares of the business's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the transaction, the chief accounting officer owned 1,526 shares in the company, valued at $1,808,325.26. The trade was a 56.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares in the company, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,500 shares of company stock valued at $15,958,170 in the last quarter. 0.14% of the stock is currently owned by company insiders.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.